文献速递乳腺癌消化系统肿瘤妇科肿瘤

COVID-19大流行措施与癌症筛查的全球关联:系统综述与Meta分析

Global Association of COVID-19 Pandemic Measures With Cancer Screening: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Oncol · 2022-01-01

该系统综述与Meta分析检索2020年1月1日至2021年12月12日发表的观察性研究及癌症登记数据,比较乳腺癌、宫颈癌和结直肠癌筛查在疫情前后检测数量的变化。结果显示疫情期间乳腺癌筛查总体下降46.7%(95%CI -55.5%至-37.8%),结直肠癌下降44.9%(95%CI -53.8%至-36.1%),宫颈癌下降51.8%(95%CI -64.7%至-38.9%),三种癌症均呈U型时间趋势,结直肠癌在2020年5月后仍显著下降(6至10月降幅23.4%[95%CI -44.4%至-2.4%])。作者结论认为这种下降可能与可避免的癌症死亡增加相关,需要有效干预以恢复筛查服务能力至疫情前水平。

要点

  • 疫情期间乳腺癌筛查总体下降46.7%(95%CI -55.5%至-37.8%)
  • 结直肠癌筛查下降44.9%(95%CI -53.8%至-36.1%),2020年6至10月仍降23.4%
  • 宫颈癌筛查下降51.8%(95%CI -64.7%至-38.9%),三种癌症均呈U型时间趋势

核心结论

  • 该系统综述与Meta分析提供了COVID-19大流行以来癌症筛查检测数量下降的汇总估计。
  • 作者认为这种下降可能与可避免的癌症死亡数量增加相关。
  • 作者提出需要有效干预以将筛查服务能力恢复至疫情前水平。

研究设计与样本

  • 系统综述与Meta分析,遵循PRISMA报告指南。
  • 检索PubMed、ProQuest、Scopus等数据库,检索2020年1月1日至2021年12月12日发表的文章。
  • 纳入报告乳腺癌、宫颈癌和结直肠癌筛查检测数量疫情前后对比数据的观察性研究及癌症登记数据文章。
  • 由两对独立评审者提取数据,计算两期间百分比变化的加权平均值。
  • 按地理区域、时期和机构类型进行分层分析。

主要发现

  • 乳腺癌筛查总体下降46.7%(95%CI -55.5%至-37.8%)。
  • 结直肠癌筛查总体下降44.9%(95%CI -53.8%至-36.1%)。
  • 宫颈癌筛查总体下降51.8%(95%CI -64.7%至-38.9%)。
  • 三种癌症均呈U型时间趋势;结直肠癌在2020年5月后仍显著下降,6至10月降幅为23.4%(95%CI -44.4%至-2.4%)。
  • 不同地理区域和筛查机构类型间存在差异。

关键数值与推荐

  • 主要结局为2020年1月至10月筛查检测数量较前一时段的加权平均百分比变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Public health services, including cancer screening tests, have been affected by the onset of the COVID-19 epidemic. OBJECTIVE: To investigate the pandemic's association with cancer screening worldwide. DATA SOURCES: In this systematic review and meta-analysis, databases such as PubMed, ProQuest, and Scopus were searched comprehensively for articles published between January 1, 2020, and December 12, 2021. STUDY SELECTION: Observational studies and articles that reported data from cancer registries that compared the number of screening tests performed before and during the pandemic for breast, cervical, and colorectal cancer were included. DATA EXTRACTION AND SYNTHESIS: Two pairs of independent reviewers extracted data from the selected studies. The weighted average of the percentage variation was calculated between the 2 periods to assess the change in the number of cancer screening tests performed during the pandemic. Stratified analysis was performed by geographic area, period, and type of setting. The systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. MAIN OUTCOMES AND MEASURES: The main outcome was the weighted average percentage variation in the number of screening tests performed between January and October 2020 compared with the previous period. RESULTS: The review comprised 39 publications. There was an overall decrease of -46.7% (95% CI, -55.5% to -37.8%) for breast cancer screening, -44.9% (95% CI, -53.8% to -36.1%) for colorectal cancer screening, and -51.8% (95% CI, -64.7% to -38.9%) for cervical cancer screening during the pandemic. For all 3 cancers, a U-shaped temporal trend was identified; for colorectal cancer, a significant decrease was still apparent after May 2020 (in June to October, the decrease was -23.4% [95% CI, -44.4% to -2.4%]). Differences by geographic area and screening setting were also identified. CONCLUSIONS AND RELEVANCE: A summary estimate of the downscaling of cancer screening tests since the onset of the COVID-19 pandemic is provided in this systematic review and meta-analysis. This could be associated with an increase in the number of avoidable cancer deaths. Effective interventions are required to restore the capacity of screening services to the prepandemic level.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Teglia F, Angelini M, Astolfi L, et al. Global Association of COVID-19 Pandemic Measures With Cancer Screening: A Systematic Review and Meta-analysis. JAMA Oncol. 2022. PMID: 35797056. doi:10.1001/jamaoncol.2022.2617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。